Cantargia AB
STO:CANTA

Watchlist Manager
Cantargia AB Logo
Cantargia AB
STO:CANTA
Watchlist
Price: 1.812 SEK -2.42% Market Closed
Market Cap: 332.8m SEK
Have any thoughts about
Cantargia AB?
Write Note

Cantargia AB
Research & Development

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Cantargia AB
Research & Development Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Research & Development CAGR 3Y CAGR 5Y CAGR 10Y
Cantargia AB
STO:CANTA
Research & Development
-kr185.2m
CAGR 3-Years
10%
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Biogaia AB
STO:BIOG B
Research & Development
-kr104.4m
CAGR 3-Years
0%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Research & Development
-kr71.7m
CAGR 3-Years
-23%
CAGR 5-Years
-1%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Research & Development
-kr115m
CAGR 3-Years
-13%
CAGR 5-Years
-6%
CAGR 10-Years
-8%
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Research & Development
-kr3.3B
CAGR 3-Years
-32%
CAGR 5-Years
-18%
CAGR 10-Years
-22%
BioArctic AB
STO:BIOA B
Research & Development
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Cantargia AB
Glance View

Market Cap
332.8m SEK
Industry
Biotechnology

Cantargia AB is a holding company, which engages in the development of antibody-based cancer treatment. The company is headquartered in Lund, Skane. The company went IPO on 2015-03-17. The firm is engaged in the development of a therapy for the treatment of cancer by targeting a cell-surface receptor on malignant stem cells, through the development of antibody therapeutics for eradication of malignant stem cells. Cantargia AB uses the Interleukin-1 receptor accessory protein (IL1RAP), as the target for development of a novel antibody-based therapy for leukemia.

CANTA Intrinsic Value
1.024 SEK
Overvaluation 44%
Intrinsic Value
Price

See Also

What is Cantargia AB's Research & Development?
Research & Development
-185.2m SEK

Based on the financial report for Sep 30, 2024, Cantargia AB's Research & Development amounts to -185.2m SEK.

What is Cantargia AB's Research & Development growth rate?
Research & Development CAGR 5Y
-14%

Over the last year, the Research & Development growth was 37%. The average annual Research & Development growth rates for Cantargia AB have been 10% over the past three years , -14% over the past five years .

Back to Top